Compare JBI & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JBI | ANL |
|---|---|---|
| Founded | 2002 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Products | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 728.3M | 611.1M |
| IPO Year | 2021 | 2022 |
| Metric | JBI | ANL |
|---|---|---|
| Price | $5.31 | $12.66 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $9.17 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 1.2M | 253.4K |
| Earning Date | 05-12-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.36 | $36.02 |
| Revenue Next Year | $3.16 | N/A |
| P/E Ratio | $12.96 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.26 | $0.88 |
| 52 Week High | $10.80 | $17.25 |
| Indicator | JBI | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 49.52 | 54.70 |
| Support Level | $4.89 | $11.86 |
| Resistance Level | $5.50 | $12.24 |
| Average True Range (ATR) | 0.15 | 1.14 |
| MACD | -0.01 | 0.31 |
| Stochastic Oscillator | 58.47 | 68.40 |
Janus International Group Inc is a manufacturer and supplier of turnkey solutions for self-storage, commercial, and industrial building Solutions. It provides products that include roll-up and swing doors, hallway systems, relocatable storage MASS (Moveable Additional Storage Structures) units, and technologies for automating facility and door operation. It is operated through two geographic regions; Janus North America and Janus International. The Janus International segment is comprised of a subsidiary whose production and sales are largely in Europe and Australia. The Janus North America segment is comprised of all the other entities.
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.